Mechanism of lithium-induced polyuria in the rat.
While many studies have demonstrated a nephrogenic diabetes insipidus syndrome (NDI) with prolonged lithium (Li) treatment, experiments in the isolated rat papillary collecting duct have suggested that the defect may be due to a circulating factor that inhibits the action of arginine vasopressin (AVP). Since Li-treatment can produce a form of hyperparathyroidism and parathyroid hormone (PTH) can act as a partial agonist to AVP, in vivo and in vitro studies were performed on rats made polyuric by daily intraperitoneal (i.p.) Li (4 mmol/kg) treatment. Li-treatment for three weeks produced an increase in PTH (194 +/- 20 compared with 118 +/- 18 pg/ml in control rats; P < 0.01) as well as an increase in the plasma calcium concentration (2.38 +/- 0.05 compared with 2.25 +/- 0.04 mmol/liter; P < 0.05). Clearance studies were performed on water loaded Li-treated and control rats, and the defect in urine concentration was only observed with a low physiological concentration of AVP (10 mU/kg body wt over 5 min). Maximal urine osmolality was 328 +/- 31 compared with 613 +/- 81 mOsm/kg (P < 0.05) in controls. There was no detectable difference with a prolonged maximal physiological AVP concentration (10 mU bolus and 50 mU/kg body wt per hr) and papillary solute concentrations were unchanged. When Li-treated rats had been parathyroidectomized (PTX), a significant difference in urine concentration with the low AVP concentration could not be demonstrated when compared to non-PTX control rats. In the isolated papillary collecting duct preparation a medium was used that contained fresh plasma from Li-treated or control rats, both intact and PTX. Experiments using plasma from Li-treated intact rats produced only a 25.4 +/- 5.1% increase in diffusional water permeability with the addition of AVP (200 microU/ml) compared to 52.6 +/- 9.0% in control rats (P < 0.01). However, when plasma from Li-treated PTX rats was used, the AVP induced increase in water permeability (54.7 +/- 11.2%) was not significantly different from that observed in PTX control rats. These studies show that the NDI-like defect in Li-treatment is small and easily overcome by higher concentrations of AVP and suggests that the concentration defect is at least in part due to increased circulating levels of PTH acting as a partial agonist to AVP and thereby inhibiting its hydroosmotic action.
Carney
S L
SL
Faculty of Medicine and Health Sciences, University of Newcastle, New South Wales, Australia.
Ray
C
C
Gillies
A H
AH
D000818:Animals; D001127:Arginine Vasopressin / Q000502:physiology; D002118:Calcium / Q000378:metabolism; D003919:Diabetes Insipidus / Q000209:etiology; D004195:Disease Models, Animal; D004231:Diuresis / Q000187:drug effects / Q000502:physiology; D005260:Female; D066298:In Vitro Techniques; D007679:Kidney Medulla / Q000187:drug effects / Q000503:physiopathology; D007685:Kidney Tubules, Collecting / Q000187:drug effects / Q000503:physiopathology; D008094:Lithium / Q000633:toxicity*; D008297:Male; D009995:Osmosis / Q000502:physiology; D010281:Parathyroid Hormone / Q000502:physiology; D016105:Parathyroidectomy; D011141:Polyuria / Q000139:chemically induced* / Q000209:etiology* / Q000503:physiopathology; D011677:Punctures; D051381:Rats; D017208:Rats, Wistar; D013577:Syndrome
D010281:Parathyroid Hormone; D001127:Arginine Vasopressin; D008094:Lithium; D002118:Calcium